Processa Pharmaceuticals, Inc.
- Open
- 2.23
- Day high
- 2.32
- Day low
- 2.21
- Prev close
- 2.24
- Volume
- 46K
- Mkt cap
- $6M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.5
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $146K over the last 3 months (29 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
Processa Pharmaceuticals, Inc. (PCSA) is a Healthcare company listed on NASDAQ. The stock is down 57% over the past year. Over the trailing 3 months, insiders filed 29 open-market buys and 0 sales (SEC Form 4).
Processa Pharmaceuticals, Inc. (PCSA) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PCSA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-1.00 | $-1.29 | -29.0% | — | — |
| Mar 19, 2026 | $-1.50 | $-18.50 | -1133.3% | — | — |
| Nov 6, 2025 | $-2.00 | $-1.75 | +12.5% | — | — |
| Aug 7, 2025 | $-0.23 | $-0.25 | -8.7% | — | — |
| May 8, 2025 | $-0.77 | $-0.30 | +61.0% | — | — |
| Mar 20, 2025 | $-0.92 | $-0.74 | +19.6% | — | — |
| Oct 30, 2024 | $-1.00 | $-1.03 | -3.0% | — | — |
| Aug 13, 2024 | $-0.98 | $-1.01 | -3.1% | — | — |
| May 10, 2024 | $-1.18 | $-1.11 | +5.9% | — | — |
| Mar 29, 2024 | $-1.60 | $-0.24 | +85.0% | — | — |
| Nov 13, 2023 | $-0.10 | $-1.60 | -1500.0% | — | — |
| Aug 10, 2023 | $-3.00 | $-2.00 | +33.3% | — | — |
PCSA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Guy Wendyofficer: Chief Administrative Officer | Buy | 2,436 | $1.93 |
| Jul 1, 2026 | Young Daviddirector, officer: Pres. Research & Development | Buy | 2,531 | $1.93 |
| Jul 1, 2026 | SKIBSTED RUSSELLofficer: Chief Financial Officer | Buy | 3,277 | $1.93 |
| Jul 1, 2026 | Ng George Kdirector, officer: Chief Executive Officer | Buy | 3,057 | $1.93 |
| Jul 1, 2026 | Lin Patrickofficer: Chief Business - Strategy Off | Buy | 2,106 | $1.93 |
| Jun 30, 2026 | Pannu Geraldinedirector | Option | 203 | — |
| Jun 30, 2026 | Neal James Rdirector | Option | 203 | — |
| Jun 30, 2026 | Baluch Khosodirector | Option | 203 | — |
| Jun 30, 2026 | Yorke Justin Wdirector | Option | 203 | — |
| Jun 16, 2026 | Guy Wendyofficer: Chief Administrative Officer | Buy | 2,118 | $2.22 |
| Jun 16, 2026 | Lin Patrickofficer: Chief Business - Strategy Off | Buy | 1,831 | $2.22 |
| Jun 16, 2026 | Ng George Kdirector, officer: Chief Executive Officer | Buy | 2,465 | $2.22 |
| Jun 16, 2026 | SKIBSTED RUSSELLofficer: Chief Financial Officer | Buy | 2,654 | $2.22 |
| Jun 16, 2026 | Young Daviddirector, officer: Pres. Research & Development | Buy | 2,067 | $2.22 |
| Jun 1, 2026 | Guy Wendyofficer: Chief Administrative Officer | Buy | 1,829 | $2.57 |
Source: PCSA SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
See the full PCSA insider & 13F page →Processa Pharmaceuticals, Inc. company profile
Overview
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a clinical-stage biopharmaceutical company founded in 2011 and based in Hanover, Maryland. The company went public in March 2014 and focuses on developing innovative drug products to address unmet medical needs, particularly in oncology and gastrointestinal disorders. Processa operates as a development-stage company with no current revenue, relying on clinical trials to advance its pipeline of potential therapeutic treatments through regulatory approval processes.
Business
Processa Pharmaceuticals operates in the biotechnology sector, specifically as a clinical-stage biopharmaceutical company developing novel drug therapies. The biotechnology industry involves using biological processes and organisms to develop medical treatments, with companies typically spending years conducting clinical trials to prove safety and efficacy before receiving regulatory approval to commercialize their products. The company's core business revolves around developing next-generation chemotherapy drugs and treatments for rare medical conditions. Their pipeline includes several key product candidates at various stages of clinical development: PCS499 represents their lead non-oncology candidate, an oral tablet currently in Phase 2B clinical trials for treating necrobiosis lipoidica, a chronic skin condition that causes disfiguring lesions. This rare disorder affects the skin's collagen and fat layers, creating painful, discolored patches that can significantly impact patients' quality of life. PCS12852 is a selective serotonin receptor agonist in Phase 2A trials targeting gastrointestinal disorders including gastroparesis (delayed stomach emptying), chronic constipation, and irritable bowel syndrome. This drug works by stimulating specific receptors that help regulate digestive tract movement. The company's oncology-focused pipeline includes three next-generation chemotherapy drugs designed to reduce side effects while maintaining or improving treatment effectiveness: PCS3117 is a cytosine analog in Phase 2B trials for pancreatic and non-small cell lung cancer. This represents an improved version of existing chemotherapy agents with potentially fewer toxic side effects. PCS6422 is an oral inhibitor in Phase 1B trials for metastatic colorectal and breast cancer, designed to enhance the effectiveness of existing chemotherapy drugs by blocking enzymes that break down cancer medications. PCS11T is an analog of existing cancer drugs irinotecan and SN38, currently in preclinical development for various cancer types. Given the company's pre-revenue status, revenue breakdown by segment is not applicable, as all efforts are focused on clinical development activities.
Revenue model
Processa Pharmaceuticals currently generates no revenue, as is typical for clinical-stage biotechnology companies. The company's future business model will depend on successfully advancing its drug candidates through clinical trials and obtaining regulatory approval from agencies like the FDA. Once approved, the company's revenue model would likely include product sales of proprietary pharmaceuticals to healthcare providers, hospitals, and patients through traditional pharmaceutical distribution channels. For rare disease treatments like PCS499, the company could command premium pricing due to limited treatment alternatives and smaller patient populations. The company may also pursue licensing agreements or partnership deals with larger pharmaceutical companies, which could provide upfront payments, milestone payments during development, and royalties on future sales. Such arrangements are common in biotechnology, allowing smaller companies to access larger partners' manufacturing, marketing, and distribution capabilities. Factors that could increase profitability margins include successful clinical trial outcomes that differentiate their products from existing treatments, obtaining orphan drug designations for rare diseases (which provide market exclusivity and tax incentives), and achieving regulatory approvals in multiple geographic markets. The company's focus on next-generation chemotherapy drugs with reduced side effects could command premium pricing if clinical data supports superior patient outcomes. Conversely, factors that could pressure margins include clinical trial failures, regulatory delays, increased competition from other biotechnology companies developing similar treatments, pricing pressure from healthcare payers and government programs, and the substantial ongoing costs of manufacturing, marketing, and post-market surveillance required for approved pharmaceuticals. The company's current cash burn rate of approximately $11-12 million annually demonstrates the significant capital requirements of drug development.
Competitive moat
Processa Pharmaceuticals operates in a highly competitive biotechnology landscape with limited sustainable moats typical of early-stage drug development companies. The company's primary competitive advantages stem from its intellectual property portfolio surrounding its drug candidates and the clinical data generated through its trials. The company's focus on next-generation chemotherapy drugs with reduced side effects could provide a differentiation advantage if clinical trials demonstrate superior safety profiles compared to existing treatments. This approach addresses a significant unmet medical need, as current chemotherapy often causes severe side effects that limit patient compliance and quality of life. For rare disease treatments like PCS499 for necrobiosis lipoidica, the company benefits from a small addressable market with limited existing treatment options, potentially reducing competitive pressure. However, this also limits the overall market opportunity. The company's moat is relatively weak due to several factors. As a clinical-stage company, Processa faces substantial execution risk - clinical trials may fail, regulatory approval is uncertain, and the company lacks the manufacturing, marketing, and distribution capabilities of established pharmaceutical companies. The biotechnology industry is characterized by high failure rates, with most drug candidates never reaching market approval. Competitive threats include larger pharmaceutical companies with greater resources developing similar treatments, generic drug manufacturers who could eventually compete with approved products, and other biotechnology companies pursuing alternative approaches to the same medical conditions. The company's limited financial resources compared to large pharmaceutical companies also constrains its ability to advance multiple programs simultaneously or weather development setbacks. The regulatory environment presents both protection and risk - while FDA approval creates barriers to entry, the approval process itself represents a significant hurdle that many companies fail to overcome. Overall, Processa's competitive position depends heavily on successful clinical execution and eventual regulatory approval, making it a high-risk, high-reward investment proposition.
Risks & safety
Processa Pharmaceuticals presents significant financial risk typical of pre-revenue biotechnology companies, with limited margin of safety for investors. • Cash Position and Burn Rate: The company held $2.9 million in cash as of Q1 2025, down from $5.6 million in Q2 2024. With annual cash burn of approximately $11-12 million based on recent operating cash flows, the company faces immediate funding needs and potential solvency risk within quarters without additional capital raising. • Debt and Solvency: Low debt levels with debt-to-equity ratio of 0.014, indicating minimal leverage. However, negative equity returns of -80% and negative free cash flows of $11.2 million annually signal unsustainable current financial trajectory without external funding. • Valuation Metrics: Current market cap of approximately $3.6 million represents extreme valuation compression. Price-to-book ratio of 1.0 and negative earnings make traditional valuation metrics less meaningful. The company trades near net asset value, suggesting market skepticism about future prospects. • Current Ratio: Strong current ratio of 2.93 indicates short-term liquidity adequacy, but this metric deteriorates rapidly given high cash burn rate. • Other Considerations: The company's survival depends entirely on successful clinical trial outcomes and ability to raise additional capital. Dilution risk is extremely high for existing shareholders given funding needs and low current stock price.
Recent development
Based on the available financial data and company description, Processa Pharmaceuticals has undergone a significant strategic pivot toward oncology over recent years. The company has repositioned itself to focus primarily on developing next-generation chemotherapy drugs designed to reduce side effects while maintaining therapeutic effectiveness. The company's 2022 earnings call revealed a clear strategic shift toward prioritizing three next-generation chemotherapy candidates: an improved version of capecitabine, an enhanced gemcitabine analog, and a next-generation irinotecan derivative. This pivot represents a move away from a more diversified pipeline toward concentrated oncology expertise. Clinical Development Progress has been the primary focus, with the company advancing multiple candidates through various trial phases. PCS3117 (next-generation capecitabine) progressed to Phase 2B trials for pancreatic and non-small cell lung cancer, while PCS6422 entered Phase 1B trials for metastatic colorectal and breast cancer. The company has been working closely with FDA through Project Optimus approaches to optimize dosing regimens and trial designs. Operational Efficiency Initiatives include increased focus on biomarker development to better identify patient populations most likely to benefit from their treatments. This precision medicine approach could improve clinical trial success rates and eventual commercial positioning. The company has also invested in visibility and investor relations efforts, expanding social media presence and engaging with the oncology community to build awareness of their development programs. However, the dramatic decline in cash position from $6.5 million at end of 2022 to under $3 million currently indicates ongoing funding challenges that may limit development activities.
PCSA company profile · for informational purposes only — not investment advice.
Track PCSA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free